---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-001413"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:41:34.988225+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CNS Pharmaceuticals appoints Lynne Kelley as CMO; former CMO Sandra Silberman departs with severance

## Summary
- Lynne Kelley appointed CMO effective March 2, 2026; base salary $450K, target bonus 40%.
- Initial RSU grant of 9,500 shares; vests 25% at 6 months, 25% at 12 months, balance quarterly.
- Severance: 6 months base salary plus prorated bonus and accelerated equity if terminated without cause.
- Former CMO Sandra Silberman receives 3 months base salary severance under separation agreement.

## SEC filing metadata
- accession: 0001683168-26-001413
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316826001413/0001683168-26-001413-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316826001413/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-001413
- JSON: https://secwatch.observer/filing/0001683168-26-001413.json
- Plain text: https://secwatch.observer/filing/0001683168-26-001413.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.